Why is this ASX All Ords share sinking 34% on Monday?

Investors have been selling off this healthcare share due to some bad news.

| More on:
A man slumps crankily over his morning coffee as it pours with rain outside.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Ltd (ASX: SPL) share price is ending the month in disastrous fashion.

In morning trade, the ASX All Ords biotechnology share is down 34% to a 52-week low of 21.5 cents.

Why is this ASX All Ords share being sold off?

Investors have been hitting the sell button in a panic on Monday after the company was dealt a major blow from pharmaceutical giant AstraZeneca plc (NASDAQ: AZN).

According to the release, AstraZeneca has made the decision to discontinue the development of AZD0466 following an internal review that was prompted by a small number of asymptomatic adverse events (AEs).

AZD0466 is a highly optimised dendrimer nanoparticle formulation of AstraZeneca's dual Bcl-2/xL inhibitor, AZD4320, which utilises Starpharma's dendrimer drug delivery technology.

The release highlights that the events were unrelated to Starpharma's dendrimer drug delivery technology. And while management believes the AEs do not adversely impact the therapeutic and commercial potential of its technology, that hasn't been enough to convince the market not to sell off this ASX All Ords share today.

Starpharma's CEO, Jackie Fairley said:

Whilst this decision is clearly not what Starpharma would have hoped for, we note that it relates to haematological malignancies and at the highest three dose groups of AZD0466 and was not due to our dendrimer technology.

DEP has demonstrated multiple benefits in Starpharma's clinical studies in patients with solid tissue tumours, including significant preferential accumulation in these tumours compared to blood levels. This development with AZD0466 does not impact Starpharma's DEP platform, the Company's internal clinical and preclinical DEP programs, or DEP partnerships. Starpharma's multi-product DEP License agreement with AstraZeneca remains in effect.

This ASX All Ords share is now down 66% over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Starpharma. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Telix share price hits record high on strong quarter and guidance upgrade

This market darling has continued to deliver stunning top line growth.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 66% in FY24, will Telix Pharmaceuticals shares continue?

After such an impressive run, has the trend exhausted?

Read more »

Man sleeping with a sleep apnoea mask on.
Healthcare Shares

Buy Resmed shares at 'attractive entry level' says top broker

Could this be the right entry point to own Resmed?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

CSL shares hit new 52-week high! What's next?

These ASX experts reckon CSL investors are still in for a treat.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

NIB shares rise as top broker calls the stock a buy

Is this stock a healthy opportunity?

Read more »

Man pointing at a blue rising share price graph.
Healthcare Shares

Why is the Nanosonics share price rocketing 10% today?

Investors are pleased with a big improvement in this company's performance.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why the ResMed share price tanked in FY 2024 and what to expect in FY 2025

Down 11% in FY 2024, is the ResMed share price poised for a big turnaround in FY 2025?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX healthcare stock rocketing 25% on Friday?

What is getting investors excited? Let's find out.

Read more »